AstraZeneca's Drug Fasenra Flops in COPD Trial AstraZeneca's Drug Fasenra Flops in COPD Trial

AstraZeneca's said its first respiratory biologic medicine Fasenra (benralizumab) failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Related Links:

The objective of the article is to identify clusters of patients with COPD according to factors known to be associated with mortality and to verify whether clusters' assignment is associated with 2-year mortality. Patients ( n = 141) were evaluated by bioelectrical impedance, maximal inspiratory pressure (MIP), one-repetition maximum test of the quadriceps femoris (1RMQF) and BODE index (body mass index; airflow obstruction (spirometry); dyspnea (modified Medical Research Council scale); and exercise capacity (6-minute walk test (6MWT) distance). Vital status was retrospectively checked 2 years after the assessments, and t...
Source: Chronic Respiratory Disease - Category: Respiratory Medicine Authors: Tags: Chron Respir Dis Source Type: research
Abstract Pain is a significant problem in stable chronic obstructive pulmonary disease (COPD) and is associated with other symptoms, worse health status and lower functional status. Not much is known about pain in unstable disease. The primary aim of the present study is to investigate prevalence, characteristics and relationships of pain in patients with COPD hospitalized for an acute exacerbation (AECOPD) and indicated for post-acute pulmonary rehabilitation (PR). This cross-sectional observational study included 149 patients (mean age 70.8 (±7.9) years, 49% male, mean forced expiratory volume in one seco...
Source: Chronic Respiratory Disease - Category: Respiratory Medicine Authors: Tags: Chron Respir Dis Source Type: research
uml;oğlu B Abstract CLINICAL TRIAL NUMBER:: NCT03319108. PMID: 30428708 [PubMed - in process]
Source: Chronic Respiratory Disease - Category: Respiratory Medicine Authors: Tags: Chron Respir Dis Source Type: research
Abstract Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are important causes of hospital admission and mortality. Pneumonia is a major contributor to hospitalization for AECOPD and has a close relationship with poor outcomes. We performed a prospective cohort study to evaluate the prognosis of AECOPD patients with or without community-acquired pneumonia (CAP) who hospitalized from January 2012 to December 2015. We investigated mortality and readmission rates within 6 months after the first admission between two groups and analyzed the difference of survival rate according to readmission dura...
Source: Chronic Respiratory Disease - Category: Respiratory Medicine Authors: Tags: Chron Respir Dis Source Type: research
Authors: Blanchard E, Piquet J, Piperno D, Pinet C, Stach B, Roche N PMID: 30429091 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
Vapotherm said today it closed its initial public offering, raising a total $64.4 million in gross proceeds. The Exeter, N.H.-based company developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. Vapotherm said it floated 4.6 million shares of its common stock at $14 per share, and that the offering featured a fully exercised underwriter’s option to pur...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Initial Public Offering (IPO) Respiratory Wall Street Beat Vapotherm Source Type: news
Elderly, those living>10 miles from facility, those with lower SES less likely to receive pulmonary rehab
Source: Pulmonary Medicine News - Doctors Lounge - Category: Respiratory Medicine Tags: Internal Medicine, Nursing, Pulmonology, Geriatrics, Journal, Source Type: news
Chronic obstructive pulmonary disease (COPD) is a progressive condition with no cure. It is not possible to completely reverse it, but there are many things a person with COPD can do to help enhance outlook and improve their quality of life.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: COPD Source Type: news
FRIDAY, Nov. 16, 2018 -- Few patients hospitalized for chronic obstructive pulmonary disorder (COPD) receive pulmonary rehabilitation (PR), according to a study published online Nov. 12 in the Annals of the American Thoracic Society. Kerry A....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Background and objective Chronic obstructive pulmonary disease (COPD) will reduce the cardiopulmonary function and increase perioperative risk. The aim of this study is to investigate the effect of preoperative short-term high intensity lung rehabilitation training on lung function and postoperative complications in patients with COPD who are eligible for lung cancer surgery. Methods We analysis of 101 patients with COPD and a diagnosis of lung cancer, with 43 patients in pulmonary rehabilitation group and 58 patients in conventional group. The pulmonary function, postoperative pulmonary complications (PPCs) and length of ...
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: AstraZeneca | Chronic Obstructive Pulmonary | Clinical Trials | Health | Respiratory Medicine